Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Technology Week Liechtenstein.
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
Allschwil, Switzerland, April 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today...
OilXCoin's Prospectus Secures First Regulatory Approval For A Very Unique Security Token Backed by Oil & Gas
Geneva, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- The Financial Market Authority (FMA) in Liechtenstein has approved the security prospectus for OilXCoin for offering in key EEA jurisdictions and establishing its presence in the Real-World...
LCX Strengthens Ties with Cardano Ecosystem, Launches Token Sale for Profila’s $ZEKE Token
Vaduz, Liechtenstein, Feb. 11, 2025 (GLOBE NEWSWIRE) -- LCX, a regulated and compliant crypto exchange, continues to expand its presence within the Cardano ecosystem by launching the token sale for Profila’s native token, $ZEKE. This collaboration...
Legacy Network Powers Up Education With Major Blockchain Move – $LGCT Set To Become Global Currency Of Learning
RUGGEL, Liechtenstein, March 28, 2025 (GLOBE NEWSWIRE) -- In a bold leap forward to redefine education worldwide, Legacy Network announces the expansion of it’s $LGCT token onto the Base blockchain. This strategic upgrade is poised to establish...
Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Approval is based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity EC approval follows positive CHMP opinion, MHRA conditional marketing...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission...
xPortal Acquires Alphalink to Drive Innovation at the Intersection of AI and Crypto
Vaduz, Liechtenstein, Jan. 24, 2025 (GLOBE NEWSWIRE) -- xPortal, the AI-powered DeFi super-app, has acquired Alphalink, a Berlin-based Web3 startup recognized for delivering delightfully simple crypto experiences through its mobile app. The...
4BIO Capital co-leads Actithera’s oversubscribed $75.5 million Series A financing
4BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures, and Sofinnova Partners, with syndicate...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) who are apolipoprotein E ε4 (ApoE ε4*)...
The European Magazine Releases Its Summer 2025 Edition
From financial reform and investment migration to AI, climate resilience and cultural diplomacy, uncover the real forces shaping Europe’s global influence. LONDON, UNITED KINGDOM, July 22, 2025 /EINPresswire.com/ -- With a high-stakes EU–China...
CariPower Becomes First Order Provider Chosen by Obyte’s Decentralized Governance
CariPower becomes the first Order Provider chosen by Obyte’s governance introduced in November 2024. Obyte is a fully decentralized DAG-based crypto network. VADUZ, LIECHTENSTEIN, March 25, 2025 /EINPresswire.com/ -- Obyte, a leading...
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted...
Veterinary Pain Management Market Growth, Opportunities, Industry Applications, Analysis and Forecast by 2032
Veterinary Pain Management Market Was valued at USD 2.2 Bn. in 2024 is expected to grow at CAGR 6.5 % from 2025 to 2032 Reaching nearly 3.64 Bn. by 2032 SAN DIEGO, CA, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Stellar Market Research...
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical...
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – Valneva SE...
Global Digital Dentistry Market Report: Projected Growth from USD 4.60 Billion in 2024 to USD 9.22 Billion by 2032
Leading companies in the digital dentistry market include 3Shape A/S, Align Technology, Inc., Dentsply Sirona, Envista, Planmeca Oy, AG, and more. NJ, UNITED STATES, April 1, 2025 /EINPresswire.com/ -- The global digital dentistry market size...
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization...